Hong Yoonki, Choi Hye-Mi, Cheong Hyun Sub, Shin Hyoung Doo, Choi Chang Min, Kim Woo Jin
Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon 200-701, Korea.
Division of Biomedical Convergence, College of Biomedical Science, and Institute of Bioscience & Biotechnology, Kangwon National University, Chuncheon 200-701, Korea.
J Clin Med. 2019 Aug 25;8(9):1307. doi: 10.3390/jcm8091307.
Lung cancer is a common form of cancer and the leading cause of cancer-related deaths worldwide. Early diagnosis using noninvasive biomarkers may play an important role in increasing the survival rate of patients with lung cancer. Biomarkers of DNA methylation in blood samples may improve the early diagnosis of lung cancer. Here, we used peripheral blood samples obtained from 150 patients diagnosed with non-small-cell lung cancer (NSCLC) and 150 healthy controls. The latter were selected by frequency matching with the 150 patients with NSCLC, based on age, sex, and smoking status. Genome-wide methylation profiles were obtained using a MethylationEPIC BeadChip Kit, which covers the 850k bp cytosine-phosphate-guanine site. This analysis showed two significant differentially methylated changes (cg12169243 [] and cg25429010 []) associated with NSCLC in current smokers, six changes (cg09245319, cg17183999 [], cg06366994 [], cg24992236 [], cg22144719, and cg22448179 [epidermal growth factor receptor]) associated with epidermal growth factor receptor mutation in patients with adenocarcinoma, and four changes (cg25021476 [], cg04989085 [], cg20905681 [], and cg26379694) associated with advanced-stage NSCLC compared with stage I NSCLC. The validation of these DNA methylation changes and further research on the related genes may help develop easily accessible biomarkers for the early diagnosis or prognosis of NSCLC.
肺癌是一种常见的癌症形式，也是全球癌症相关死亡的主要原因。使用非侵入性生物标志物进行早期诊断可能在提高肺癌患者的生存率方面发挥重要作用。血液样本中DNA甲基化的生物标志物可能会改善肺癌的早期诊断。在此，我们使用了从150例被诊断为非小细胞肺癌（NSCLC）的患者和150名健康对照者中获取的外周血样本。后者是根据年龄、性别和吸烟状况与150例NSCLC患者进行频率匹配后挑选出来的。使用甲基化EPIC BeadChip试剂盒获得全基因组甲基化谱，该试剂盒覆盖850k bp的胞嘧啶-磷酸-鸟嘌呤位点。该分析显示，当前吸烟者中与NSCLC相关的有两个显著的差异甲基化变化（cg12169243 []和cg25429010 []），腺癌患者中与表皮生长因子受体突变相关的有六个变化（cg09245319、cg17183999 []、cg06366994 []、cg24992236 []、cg22144719和cg22448179 [表皮生长因子受体]），与I期NSCLC相比，晚期NSCLC相关的有四个变化（cg25021476 []、cg04989085 []、cg20905681 []和cg26379694）。对这些DNA甲基化变化的验证以及对相关基因的进一步研究可能有助于开发易于获取的生物标志物，用于NSCLC的早期诊断或预后评估。
